| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 25 | 2024 | 979 | 2.220 |
Why?
|
| Cerebral Hemorrhage | 12 | 2024 | 143 | 1.720 |
Why?
|
| Brain Ischemia | 9 | 2022 | 264 | 0.980 |
Why?
|
| Telemedicine | 6 | 2024 | 438 | 0.750 |
Why?
|
| Kentucky | 15 | 2024 | 28 | 0.640 |
Why?
|
| Antibodies, Monoclonal | 1 | 2024 | 1026 | 0.590 |
Why?
|
| Ohio | 13 | 2024 | 87 | 0.540 |
Why?
|
| Health Status Disparities | 4 | 2024 | 229 | 0.370 |
Why?
|
| Fibrinolytic Agents | 5 | 2022 | 193 | 0.370 |
Why?
|
| Tissue Plasminogen Activator | 4 | 2022 | 115 | 0.340 |
Why?
|
| Subarachnoid Hemorrhage | 2 | 2024 | 71 | 0.340 |
Why?
|
| Emergency Medical Services | 4 | 2018 | 397 | 0.330 |
Why?
|
| Stroke Rehabilitation | 2 | 2020 | 59 | 0.320 |
Why?
|
| Aged, 80 and over | 16 | 2024 | 6558 | 0.320 |
Why?
|
| Hyperglycemia | 2 | 2014 | 227 | 0.320 |
Why?
|
| Sex Factors | 7 | 2020 | 1282 | 0.320 |
Why?
|
| Aged | 27 | 2024 | 19739 | 0.310 |
Why?
|
| Veterans | 5 | 2024 | 1747 | 0.300 |
Why?
|
| Brain | 2 | 2012 | 3012 | 0.290 |
Why?
|
| Hypertension | 3 | 2024 | 1332 | 0.290 |
Why?
|
| Blood Pressure | 3 | 2024 | 1377 | 0.260 |
Why?
|
| Middle Aged | 25 | 2024 | 26827 | 0.260 |
Why?
|
| Mushroom Bodies | 1 | 2005 | 47 | 0.240 |
Why?
|
| Humans | 46 | 2024 | 125439 | 0.230 |
Why?
|
| Intracranial Aneurysm | 2 | 2018 | 90 | 0.230 |
Why?
|
| Alzheimer Disease | 2 | 2024 | 798 | 0.220 |
Why?
|
| Apolipoprotein E2 | 2 | 2014 | 13 | 0.220 |
Why?
|
| Migraine Disorders | 1 | 2024 | 63 | 0.210 |
Why?
|
| Male | 31 | 2024 | 61628 | 0.210 |
Why?
|
| Glucosephosphate Dehydrogenase Deficiency | 1 | 2023 | 9 | 0.210 |
Why?
|
| Cerebrovascular Disorders | 1 | 2024 | 121 | 0.210 |
Why?
|
| Risk Factors | 12 | 2024 | 10298 | 0.200 |
Why?
|
| Neurology | 1 | 2024 | 107 | 0.200 |
Why?
|
| Opiate Alkaloids | 1 | 2022 | 3 | 0.200 |
Why?
|
| Emergency Service, Hospital | 6 | 2022 | 1070 | 0.200 |
Why?
|
| Amyloid beta-Peptides | 1 | 2024 | 212 | 0.200 |
Why?
|
| Axons | 1 | 2005 | 371 | 0.200 |
Why?
|
| Endocarditis | 1 | 2023 | 106 | 0.190 |
Why?
|
| Incidence | 7 | 2024 | 3135 | 0.190 |
Why?
|
| Female | 29 | 2024 | 66888 | 0.190 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2017 | 730 | 0.180 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2024 | 205 | 0.180 |
Why?
|
| Poverty | 1 | 2024 | 422 | 0.180 |
Why?
|
| Cocaine | 1 | 2022 | 205 | 0.170 |
Why?
|
| Recurrence | 1 | 2024 | 1394 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 509 | 0.170 |
Why?
|
| Drosophila Proteins | 1 | 2005 | 713 | 0.160 |
Why?
|
| Delivery of Health Care, Integrated | 1 | 2021 | 125 | 0.160 |
Why?
|
| Education, Medical, Graduate | 1 | 2024 | 520 | 0.160 |
Why?
|
| Continuity of Patient Care | 1 | 2021 | 153 | 0.160 |
Why?
|
| Thrombolytic Therapy | 3 | 2022 | 200 | 0.160 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2014 | 3175 | 0.160 |
Why?
|
| Ischemic Attack, Transient | 1 | 2019 | 57 | 0.160 |
Why?
|
| Time Factors | 8 | 2024 | 6324 | 0.160 |
Why?
|
| Guideline Adherence | 2 | 2019 | 375 | 0.160 |
Why?
|
| Nuclear Proteins | 1 | 2005 | 1284 | 0.160 |
Why?
|
| Prospective Studies | 8 | 2017 | 6174 | 0.150 |
Why?
|
| Case-Control Studies | 6 | 2016 | 3310 | 0.150 |
Why?
|
| Certification | 1 | 2019 | 66 | 0.150 |
Why?
|
| Deprescriptions | 1 | 2017 | 12 | 0.140 |
Why?
|
| Substance-Related Disorders | 1 | 2022 | 462 | 0.140 |
Why?
|
| Cerebral Arteries | 1 | 2018 | 83 | 0.140 |
Why?
|
| Platelet Transfusion | 1 | 2017 | 53 | 0.140 |
Why?
|
| Regional Blood Flow | 1 | 2018 | 209 | 0.140 |
Why?
|
| Patient Satisfaction | 1 | 2020 | 475 | 0.140 |
Why?
|
| Hospitals, Urban | 1 | 2017 | 97 | 0.140 |
Why?
|
| Troponin | 1 | 2017 | 77 | 0.130 |
Why?
|
| Cerebral Angiography | 1 | 2017 | 101 | 0.130 |
Why?
|
| Healthcare Disparities | 2 | 2021 | 438 | 0.130 |
Why?
|
| Cholinesterase Inhibitors | 1 | 2017 | 100 | 0.130 |
Why?
|
| Prevalence | 5 | 2024 | 2469 | 0.130 |
Why?
|
| Retrospective Studies | 11 | 2024 | 16362 | 0.130 |
Why?
|
| Triage | 1 | 2017 | 139 | 0.130 |
Why?
|
| Epilepsy | 1 | 2024 | 874 | 0.130 |
Why?
|
| Amino Acid Metabolism, Inborn Errors | 1 | 2017 | 101 | 0.130 |
Why?
|
| Urban Population | 1 | 2017 | 228 | 0.130 |
Why?
|
| Post-Exposure Prophylaxis | 1 | 2015 | 11 | 0.120 |
Why?
|
| Cerebral Small Vessel Diseases | 1 | 2015 | 10 | 0.120 |
Why?
|
| Cerebral Ventricles | 1 | 2016 | 82 | 0.120 |
Why?
|
| Gait Disorders, Neurologic | 1 | 2016 | 45 | 0.120 |
Why?
|
| Urinary Incontinence | 1 | 2016 | 70 | 0.120 |
Why?
|
| Glycoproteins | 1 | 2018 | 367 | 0.120 |
Why?
|
| Neurons | 1 | 2005 | 1943 | 0.120 |
Why?
|
| Platelet Aggregation Inhibitors | 2 | 2017 | 265 | 0.120 |
Why?
|
| Genotype | 4 | 2014 | 2569 | 0.120 |
Why?
|
| Hyperlipidemias | 1 | 2016 | 178 | 0.120 |
Why?
|
| Atrial Fibrillation | 1 | 2022 | 657 | 0.110 |
Why?
|
| Practice Guidelines as Topic | 2 | 2017 | 1272 | 0.110 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2014 | 140 | 0.110 |
Why?
|
| Warfarin | 1 | 2014 | 117 | 0.100 |
Why?
|
| Contrast Media | 1 | 2017 | 480 | 0.100 |
Why?
|
| White Matter | 1 | 2015 | 184 | 0.100 |
Why?
|
| Intracranial Hemorrhages | 1 | 2013 | 77 | 0.100 |
Why?
|
| Apolipoproteins E | 1 | 2013 | 192 | 0.100 |
Why?
|
| SOXF Transcription Factors | 1 | 2012 | 18 | 0.100 |
Why?
|
| Anticonvulsants | 1 | 2015 | 384 | 0.100 |
Why?
|
| Kidney Diseases | 1 | 2017 | 485 | 0.100 |
Why?
|
| Heart Diseases | 1 | 2017 | 496 | 0.100 |
Why?
|
| Adult | 8 | 2024 | 29635 | 0.100 |
Why?
|
| Sleep | 1 | 2015 | 346 | 0.100 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2015 | 205 | 0.090 |
Why?
|
| Treatment Outcome | 9 | 2017 | 12303 | 0.090 |
Why?
|
| Echocardiography | 1 | 2017 | 1062 | 0.090 |
Why?
|
| United States | 6 | 2024 | 10924 | 0.080 |
Why?
|
| RNA, Long Noncoding | 1 | 2012 | 217 | 0.080 |
Why?
|
| Peptides | 1 | 2013 | 812 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2017 | 649 | 0.080 |
Why?
|
| Genome-Wide Association Study | 2 | 2014 | 1694 | 0.080 |
Why?
|
| Gene Expression Regulation | 1 | 2018 | 2524 | 0.080 |
Why?
|
| United States Department of Veterans Affairs | 2 | 2024 | 669 | 0.080 |
Why?
|
| Multivariate Analysis | 3 | 2017 | 1430 | 0.080 |
Why?
|
| Phenotype | 1 | 2018 | 4269 | 0.070 |
Why?
|
| Age Factors | 3 | 2020 | 2828 | 0.070 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2017 | 1271 | 0.070 |
Why?
|
| Referral and Consultation | 2 | 2021 | 543 | 0.070 |
Why?
|
| Reperfusion Injury | 1 | 2006 | 114 | 0.060 |
Why?
|
| Cohort Studies | 3 | 2023 | 4843 | 0.060 |
Why?
|
| Guanine Nucleotide Exchange Factors | 1 | 2005 | 92 | 0.060 |
Why?
|
| Cardiovascular Diseases | 1 | 2017 | 1960 | 0.060 |
Why?
|
| Headache Disorders | 1 | 2024 | 4 | 0.060 |
Why?
|
| Larva | 1 | 2005 | 248 | 0.060 |
Why?
|
| Neuropeptides | 1 | 2005 | 113 | 0.060 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2005 | 461 | 0.060 |
Why?
|
| Animals, Genetically Modified | 1 | 2005 | 312 | 0.060 |
Why?
|
| Green Fluorescent Proteins | 1 | 2005 | 387 | 0.060 |
Why?
|
| Neurologists | 1 | 2024 | 17 | 0.060 |
Why?
|
| Embryonic Development | 1 | 2005 | 211 | 0.050 |
Why?
|
| Follow-Up Studies | 3 | 2017 | 5174 | 0.050 |
Why?
|
| Phosphoproteins | 1 | 2005 | 420 | 0.050 |
Why?
|
| Saccharomyces cerevisiae Proteins | 1 | 2005 | 280 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2017 | 1253 | 0.050 |
Why?
|
| Social Class | 1 | 2024 | 190 | 0.050 |
Why?
|
| Educational Status | 1 | 2024 | 276 | 0.050 |
Why?
|
| Severity of Illness Index | 3 | 2017 | 2912 | 0.050 |
Why?
|
| Logistic Models | 2 | 2017 | 1808 | 0.050 |
Why?
|
| Environmental Exposure | 1 | 2024 | 220 | 0.050 |
Why?
|
| Demography | 1 | 2023 | 239 | 0.050 |
Why?
|
| Costs and Cost Analysis | 1 | 2022 | 163 | 0.050 |
Why?
|
| Fellowships and Scholarships | 1 | 2024 | 282 | 0.050 |
Why?
|
| Fee-for-Service Plans | 1 | 2021 | 18 | 0.050 |
Why?
|
| Emotions | 1 | 2024 | 358 | 0.040 |
Why?
|
| Insurance, Health, Reimbursement | 1 | 2021 | 34 | 0.040 |
Why?
|
| Occupational Health | 1 | 2021 | 43 | 0.040 |
Why?
|
| Animals | 4 | 2018 | 34310 | 0.040 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 2005 | 1006 | 0.040 |
Why?
|
| Aftercare | 1 | 2022 | 149 | 0.040 |
Why?
|
| Models, Biological | 1 | 2005 | 1466 | 0.040 |
Why?
|
| Rats | 2 | 2018 | 3727 | 0.040 |
Why?
|
| Drosophila melanogaster | 1 | 2005 | 771 | 0.040 |
Why?
|
| Recombinant Proteins | 2 | 2013 | 1400 | 0.040 |
Why?
|
| Stroke Volume | 1 | 2022 | 495 | 0.040 |
Why?
|
| Curriculum | 1 | 2024 | 726 | 0.040 |
Why?
|
| Hospitals | 1 | 2022 | 399 | 0.040 |
Why?
|
| Analgesics, Opioid | 1 | 2023 | 408 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2019 | 305 | 0.040 |
Why?
|
| Ventricular Function, Left | 1 | 2022 | 514 | 0.040 |
Why?
|
| Rats, Inbred BN | 1 | 2018 | 16 | 0.040 |
Why?
|
| Patient-Centered Care | 1 | 2020 | 221 | 0.040 |
Why?
|
| Basilar Artery | 1 | 2018 | 26 | 0.040 |
Why?
|
| Health Care Costs | 1 | 2021 | 372 | 0.040 |
Why?
|
| Registries | 1 | 2024 | 1434 | 0.040 |
Why?
|
| Ligation | 1 | 2018 | 133 | 0.040 |
Why?
|
| Patient Discharge | 1 | 2022 | 497 | 0.040 |
Why?
|
| Rats, Long-Evans | 1 | 2018 | 102 | 0.040 |
Why?
|
| Glasgow Coma Scale | 1 | 2018 | 206 | 0.040 |
Why?
|
| Intracranial Hemorrhage, Traumatic | 1 | 2017 | 11 | 0.040 |
Why?
|
| Ventriculostomy | 1 | 2017 | 36 | 0.030 |
Why?
|
| Halogenation | 1 | 2017 | 5 | 0.030 |
Why?
|
| Microarray Analysis | 1 | 2018 | 237 | 0.030 |
Why?
|
| Anticoagulants | 1 | 2022 | 578 | 0.030 |
Why?
|
| Patient Safety | 1 | 2021 | 398 | 0.030 |
Why?
|
| Communication | 1 | 2020 | 515 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2017 | 143 | 0.030 |
Why?
|
| Disease Models, Animal | 2 | 2018 | 4405 | 0.030 |
Why?
|
| Chi-Square Distribution | 1 | 2017 | 586 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2019 | 391 | 0.030 |
Why?
|
| Mortality | 1 | 2017 | 238 | 0.030 |
Why?
|
| Time-to-Treatment | 1 | 2017 | 186 | 0.030 |
Why?
|
| Rats, Inbred WKY | 1 | 2015 | 54 | 0.030 |
Why?
|
| Rats, Inbred SHR | 1 | 2015 | 65 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2018 | 408 | 0.030 |
Why?
|
| Young Adult | 2 | 2022 | 9085 | 0.030 |
Why?
|
| Thrombocytopenia | 1 | 2017 | 225 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2005 | 2603 | 0.030 |
Why?
|
| Delivery of Health Care | 1 | 2021 | 617 | 0.030 |
Why?
|
| Age of Onset | 1 | 2015 | 601 | 0.030 |
Why?
|
| Signal Transduction | 1 | 2006 | 4595 | 0.030 |
Why?
|
| National Institute of Neurological Disorders and Stroke (U.S.) | 1 | 2013 | 8 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 1494 | 0.030 |
Why?
|
| Proportional Hazards Models | 1 | 2016 | 1361 | 0.030 |
Why?
|
| Quantitative Trait Loci | 1 | 2014 | 287 | 0.020 |
Why?
|
| Risk | 1 | 2014 | 759 | 0.020 |
Why?
|
| Disease Progression | 1 | 2018 | 2083 | 0.020 |
Why?
|
| Mutation | 1 | 2005 | 5903 | 0.020 |
Why?
|
| RNA, Messenger | 1 | 2018 | 2812 | 0.020 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2017 | 732 | 0.020 |
Why?
|
| Electronic Health Records | 1 | 2018 | 724 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2013 | 1173 | 0.020 |
Why?
|
| Double-Blind Method | 1 | 2013 | 1635 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2017 | 2091 | 0.020 |
Why?
|
| Cross-Sectional Studies | 1 | 2017 | 3433 | 0.020 |
Why?
|
| Prognosis | 1 | 2017 | 4690 | 0.020 |
Why?
|
| Smoking | 1 | 2012 | 1049 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2012 | 2652 | 0.010 |
Why?
|
| Child | 1 | 2022 | 24606 | 0.010 |
Why?
|